18302222

Source:http://linkedlifedata.com/resource/pubmed/id/18302222

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0205100, umls-concept:C0278348, umls-concept:C0376358, umls-concept:C1704410
pubmed:issue	7
pubmed:dateCreated	2008-4-22
pubmed:abstractText	Failure of cancer immunotherapy is essentially due to immunological tolerance to tumor-associated antigens (TAAs), as these antigens are also expressed in healthy tissues.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P50 DK065313, http://linkedlifedata.com/resource/pubmed/grant/R01 CA82419
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8101368
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Polyomavirus Transforming, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0270-4137
pubmed:author	pubmed-author:ArredouaniMohamed SMS, pubmed-author:EngMarvin HMH, pubmed-author:HollenbeckBrentB, pubmed-author:NeeleyYilin CYC, pubmed-author:RubinMark AMA, pubmed-author:SandaMartin GMG
pubmed:copyrightInfo	(c) 2008 Wiley-Liss, Inc.
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	68
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	715-27
pubmed:meshHeading	pubmed-meshheading:18302222-Adenocarcinoma, pubmed-meshheading:18302222-Animals, pubmed-meshheading:18302222-Antigens, Polyomavirus Transforming, pubmed-meshheading:18302222-Antineoplastic Agents, pubmed-meshheading:18302222-Blotting, Southern, pubmed-meshheading:18302222-Blotting, Western, pubmed-meshheading:18302222-Cancer Vaccines, pubmed-meshheading:18302222-Cell Line, Tumor, pubmed-meshheading:18302222-Cytotoxicity, Immunologic, pubmed-meshheading:18302222-Immune Tolerance, pubmed-meshheading:18302222-Immunoenzyme Techniques, pubmed-meshheading:18302222-Immunotherapy, Adoptive, pubmed-meshheading:18302222-Male, pubmed-meshheading:18302222-Mice, pubmed-meshheading:18302222-Mice, Inbred C57BL, pubmed-meshheading:18302222-Mice, SCID, pubmed-meshheading:18302222-Neoplasm Transplantation, pubmed-meshheading:18302222-Prostatic Neoplasms, pubmed-meshheading:18302222-Recombinant Proteins, pubmed-meshheading:18302222-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:18302222-T-Lymphocytes, Cytotoxic, pubmed-meshheading:18302222-Vaccinia virus, pubmed-meshheading:18302222-Xenograft Model Antitumor Assays
pubmed:year	2008
pubmed:articleTitle	Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
pubmed:affiliation	Department of Urology, Surgery, and Pathology, University of Michigan. Ann Arbor, Michigan, USA.
pubmed:publicationType	Journal Article, Research Support, N.I.H., Extramural